Intellipharmaceutics International Inc. (IPCIF)
USD 0.15
(N/A%)
USD 0.15
(N/A%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 2.24 Million USD | 0.0% |
| 2022 | 2.24 Million USD | 95.76% |
| 2021 | 1.14 Million USD | -40.05% |
| 2020 | 1.91 Million USD | 139.38% |
| 2019 | -4.85 Million USD | -699.79% |
| 2018 | -606.59 Thousand USD | 76.98% |
| 2017 | -2.63 Million USD | -1213.17% |
| 2016 | -200.64 Thousand USD | 92.82% |
| 2015 | -2.79 Million USD | -301.22% |
| 2014 | 1.38 Million USD | 447.67% |
| 2013 | -399.25 Thousand USD | 91.47% |
| 2012 | -4.67 Million USD | -502.97% |
| 2011 | -775.9 Thousand USD | 90.26% |
| 2010 | -7.96 Million USD | -15.63% |
| 2009 | -6.88 Million USD | 70.72% |
| 2008 | -23.53 Million USD | -23.95% |
| 2007 | -18.98 Million USD | -47.18% |
| 2006 | -12.9 Million USD | -187.05% |
| 2005 | -4.49 Million USD | -30.34% |
| 2004 | -3.44 Million USD | -166.49% |
| 2003 | -1.29 Million USD | -71.36% |
| 2002 | -755.05 Thousand USD | 50.19% |
| 2001 | -1.51 Million USD | -116.43% |
| 2000 | -700.41 Thousand USD | -0.22% |
| 1999 | -698.86 Thousand USD | -98.9% |
| 1998 | -351.37 Thousand USD | 91.55% |
| 1997 | -4.15 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 2.08 Million USD | -6.48% |
| 2024 Q3 | 1.81 Million USD | -12.78% |
| 2024 Q1 | 2.22 Million USD | -0.59% |
| 2023 Q3 | 1.92 Million USD | 14.76% |
| 2023 FY | 2.24 Million USD | 0.0% |
| 2023 Q2 | 1.67 Million USD | -9.69% |
| 2023 Q4 | 2.24 Million USD | 16.43% |
| 2023 Q1 | 1.85 Million USD | 62.22% |
| 2022 FY | 2.24 Million USD | 95.76% |
| 2022 Q1 | 1.85 Million USD | -2.8% |
| 2022 Q2 | -534.56 Thousand USD | -128.79% |
| 2022 Q3 | 812.42 Thousand USD | 251.98% |
| 2022 Q4 | 1.14 Million USD | 40.99% |
| 2021 Q1 | 1.86 Million USD | 1.14% |
| 2021 Q4 | 1.91 Million USD | 68.56% |
| 2021 Q2 | 1.85 Million USD | -0.36% |
| 2021 Q3 | 1.13 Million USD | -38.87% |
| 2021 FY | 1.14 Million USD | -40.05% |
| 2020 Q1 | -1.32 Million USD | 72.72% |
| 2020 FY | 1.91 Million USD | 139.38% |
| 2020 Q2 | 476.37 Thousand USD | 136.0% |
| 2020 Q3 | 1.6 Million USD | 235.98% |
| 2020 Q4 | 1.84 Million USD | 14.96% |
| 2019 FY | -4.85 Million USD | -699.79% |
| 2019 Q4 | -4.85 Million USD | -478.56% |
| 2019 Q2 | -38.06 Thousand USD | -103.67% |
| 2019 Q3 | 1.28 Million USD | 3466.57% |
| 2019 Q1 | 1.03 Million USD | 270.82% |
| 2018 Q1 | -1.05 Million USD | 59.99% |
| 2018 FY | -606.59 Thousand USD | 76.98% |
| 2018 Q4 | -606.59 Thousand USD | -204.34% |
| 2018 Q3 | 581.36 Thousand USD | 384.99% |
| 2018 Q2 | -203.99 Thousand USD | 80.65% |
| 2017 Q3 | -469 Thousand USD | -134.94% |
| 2017 FY | -2.63 Million USD | -1213.17% |
| 2017 Q1 | 1.09 Million USD | 643.88% |
| 2017 Q2 | 1.34 Million USD | 22.99% |
| 2017 Q4 | -2.63 Million USD | -461.8% |
| 2016 FY | -200.64 Thousand USD | 92.82% |
| 2016 Q2 | -1.49 Million USD | 45.33% |
| 2016 Q1 | -2.74 Million USD | 1.83% |
| 2016 Q3 | -1.2 Million USD | 19.78% |
| 2016 Q4 | -200.64 Thousand USD | 83.31% |
| 2015 Q4 | -2.79 Million USD | 29.51% |
| 2015 Q1 | -4.17 Million USD | -400.55% |
| 2015 Q2 | -5.82 Million USD | -39.54% |
| 2015 Q3 | -3.96 Million USD | 31.94% |
| 2015 FY | -2.79 Million USD | -301.22% |
| 2014 Q2 | -146.04 Thousand USD | -115.59% |
| 2014 Q1 | 936.54 Thousand USD | 334.58% |
| 2014 Q3 | -934.59 Thousand USD | -539.93% |
| 2014 FY | 1.38 Million USD | 447.67% |
| 2014 Q4 | 1.38 Million USD | 248.52% |
| 2013 Q1 | -2.5 Million USD | 46.56% |
| 2013 Q2 | -4.81 Million USD | -92.73% |
| 2013 FY | -399.25 Thousand USD | 91.47% |
| 2013 Q3 | -2.76 Million USD | 42.69% |
| 2013 Q4 | -399.25 Thousand USD | 85.54% |
| 2012 Q2 | -8.47 Million USD | 19.52% |
| 2012 Q3 | -7.05 Million USD | 16.78% |
| 2012 Q4 | -4.67 Million USD | 33.66% |
| 2012 FY | -4.67 Million USD | -502.97% |
| 2012 Q1 | -10.53 Million USD | -1257.13% |
| 2011 FY | -775.9 Thousand USD | 90.26% |
| 2011 Q2 | -4.03 Million USD | 19.37% |
| 2011 Q4 | -775.9 Thousand USD | 66.76% |
| 2011 Q3 | -2.33 Million USD | 42.19% |
| 2011 Q1 | -5 Million USD | 37.14% |
| 2010 Q1 | -5.77 Million USD | 16.16% |
| 2010 Q2 | -5.35 Million USD | 7.34% |
| 2010 Q3 | -4.42 Million USD | 17.38% |
| 2010 Q4 | -7.96 Million USD | -80.15% |
| 2010 FY | -7.96 Million USD | -15.63% |
| 2009 Q4 | -6.88 Million USD | 25.23% |
| 2009 Q1 | -20.33 Million USD | 13.59% |
| 2009 Q2 | -12.45 Million USD | 38.73% |
| 2009 Q3 | -9.21 Million USD | 26.05% |
| 2009 FY | -6.88 Million USD | 70.72% |
| 2008 Q4 | -23.53 Million USD | 14.64% |
| 2008 FY | -23.53 Million USD | -23.95% |
| 2008 Q3 | -27.56 Million USD | 3.95% |
| 2008 Q2 | -28.7 Million USD | -59.42% |
| 2008 Q1 | -18 Million USD | 5.18% |
| 2007 Q1 | -10.28 Million USD | 20.3% |
| 2007 Q2 | -9.68 Million USD | 5.83% |
| 2007 Q3 | -138.89 Thousand USD | 98.57% |
| 2007 Q4 | -18.98 Million USD | -13569.1% |
| 2007 FY | -18.98 Million USD | -47.18% |
| 2006 Q3 | -54.78 Million USD | 19.67% |
| 2006 FY | -12.9 Million USD | -187.05% |
| 2006 Q2 | -68.2 Million USD | -3.31% |
| 2006 Q1 | -66.01 Million USD | -1368.97% |
| 2006 Q4 | -12.9 Million USD | 76.45% |
| 2005 FY | -4.49 Million USD | -30.34% |
| 2005 Q4 | -4.49 Million USD | -134.25% |
| 2005 Q3 | -1.91 Million USD | -250.97% |
| 2005 Q2 | -546.62 Thousand USD | 61.72% |
| 2005 Q1 | -1.42 Million USD | 58.59% |
| 2004 Q3 | -1.48 Million USD | -60.79% |
| 2004 Q2 | -920.58 Thousand USD | -49.31% |
| 2004 Q1 | -616.54 Thousand USD | 52.35% |
| 2004 FY | -3.44 Million USD | -166.49% |
| 2004 Q4 | -3.44 Million USD | -132.94% |
| 2003 Q4 | -1.29 Million USD | 5.31% |
| 2003 Q3 | -1.36 Million USD | -48.27% |
| 2003 Q2 | -921.56 Thousand USD | 41.14% |
| 2003 Q1 | -1.56 Million USD | -107.35% |
| 2003 FY | -1.29 Million USD | -71.36% |
| 2002 Q1 | -652 Thousand USD | 56.99% |
| 2002 Q2 | -677.99 Thousand USD | -3.99% |
| 2002 Q3 | -599.99 Thousand USD | 11.5% |
| 2002 Q4 | -755.05 Thousand USD | -25.84% |
| 2002 FY | -755.05 Thousand USD | 50.19% |
| 2001 Q3 | -1.66 Million USD | 28.37% |
| 2001 FY | -1.51 Million USD | -116.43% |
| 2001 Q1 | -13.93 Million USD | -1889.25% |
| 2001 Q2 | -2.32 Million USD | 83.3% |
| 2001 Q4 | -1.51 Million USD | 9.05% |
| 2000 Q4 | -700.41 Thousand USD | 22.07% |
| 2000 FY | -700.41 Thousand USD | -0.22% |
| 2000 Q1 | -5.7 Million USD | -716.48% |
| 2000 Q3 | -898.78 Thousand USD | 46.98% |
| 2000 Q2 | -1.69 Million USD | 70.29% |
| 1999 Q3 | -316.37 Thousand USD | 53.92% |
| 1999 Q2 | -686.53 Thousand USD | -388.53% |
| 1999 Q1 | -140.52 Thousand USD | 60.01% |
| 1999 Q4 | -698.86 Thousand USD | -120.9% |
| 1999 FY | -698.86 Thousand USD | -98.9% |
| 1998 FY | -351.37 Thousand USD | 91.55% |
| 1998 Q1 | -5.18 Million USD | 0.0% |
| 1998 Q2 | -4.13 Million USD | 20.28% |
| 1998 Q3 | -6.76 Million USD | -63.63% |
| 1998 Q4 | -351.37 Thousand USD | 94.81% |
| 1997 FY | -4.15 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 171262.824% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 60.303% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 94.76% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 998.259% |
| Rebus Holdings, Inc. | 305 Thousand USD | -635.158% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 135.565% |
| Qrons Inc. | 351.42 Thousand USD | -538.037% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -260.277% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 94.838% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 11087.03% |
| Skye Bioscience, Inc. | -5.72 Million USD | 139.19% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 85.775% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 45.551% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -457.979% |
| SQZ Biotechnologies Company | -36.23 Million USD | 106.188% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -141.832% |
| Mesoblast Limited | 55.85 Million USD | 95.986% |
| Marizyme, Inc. | 18.56 Million USD | 87.925% |
| Genus plc | 190.6 Million USD | 98.824% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -0.286% |
| Pharming Group N.V. | 109.8 Million USD | 97.958% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -160.652% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -84.715% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -229.74% |
| ContraFect Corporation | -6.02 Million USD | 137.209% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -1565.367% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -94.061% |
| IMV Inc. | 7.67 Million USD | 70.768% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 59.246% |
| MultiCell Technologies, Inc. | 90.04 USD | -2490163.216% |
| ONE Bio Corp. | 9.04 Million USD | 75.197% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 405.49% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 82.68% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | -63.909% |
| Q BioMed Inc. | 4.06 Million USD | 44.773% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 92.661% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -122.506% |
| Biomind Labs Inc. | 711.4 Thousand USD | -215.185% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 96.297% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -12.146% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 82.492% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -523.345% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -1503.84% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -11186.218% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -1.828% |
| GB Sciences, Inc. | 1.74 Million USD | -28.324% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 1320.011% |
| HST Global, Inc. | 96.79 Thousand USD | -2216.524% |
| CSL Limited | 10.52 Billion USD | 99.979% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -987.317% |
| Halberd Corporation | 144.72 Thousand USD | -1449.349% |
| Enzolytics Inc. | 981.65 Thousand USD | -128.413% |
| Agentix Corp. | 37.63 Thousand USD | -5858.473% |
| Resverlogix Corp. | 6.45 Million USD | 65.242% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 433.126% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.111% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 104.769% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 68.29% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 17.218% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 125.365% |
| AVAX Technologies, Inc. | -5.9 Million USD | 137.983% |
| Zenith Capital Corp. | 10.06 Thousand USD | -22179.74% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.211% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -1018.7% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 6.027% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -1262.985% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 12340.599% |
| Kadimastem Ltd | -253.1 Thousand USD | 985.901% |
| Helix BioMedix, Inc. | -2.57 Million USD | 187.245% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 88.941% |
| BioStem Technologies, Inc. | 4.47 Million USD | 49.861% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -1014.131% |
| LadRx Corporation | -2.03 Million USD | 210.104% |
| Cell Source, Inc. | 9.23 Million USD | 75.712% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -253.015% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -253.015% |
| NovAccess Global Inc. | 2.17 Million USD | -2.927% |
| Affymax, Inc. | -5.59 Million USD | 140.061% |
| Itoco Inc. | 228.3 Thousand USD | -882.122% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -1548.834% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 54.766% |
| Mobile Lads Corp. | 484.23 Thousand USD | -363.049% |
| CytoDyn Inc. | 20.26 Million USD | 88.934% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 346658.423% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 24292.39% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 70.903% |
| SYBLEU INC | 473.71 Thousand USD | -373.331% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 49.692% |
| International Stem Cell Corporation | 2.59 Million USD | 13.427% |
| Bioxytran, Inc. | 1.89 Million USD | -18.08% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -3492.574% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -2.812% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 34.705% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 73.784% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -190.217% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 279.379% |
| Neutra Corp. | 52.18 Thousand USD | -4196.536% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 190.086% |
| PureTech Health plc | -167.19 Million USD | 101.341% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 1015.541% |
| IXICO plc | -4.44 Million USD | 150.449% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 83.038% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 95.912% |
| CSL Limited | 10.52 Billion USD | 99.979% |
| Cellectis S.A. | -43.81 Million USD | 105.117% |